ClinicalTrials.Veeva

Menu

CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

T

The 920th Hospital of The Joint Logistics Support Force of the Chinese People's Liberation Army

Status and phase

Enrolling
Early Phase 1

Conditions

Relapsed or Refractory B-cell Non-hodgkin Lymphoma
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Treatments

Biological: Anti-CD19 Universal CAR-T Cells injection

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05105867
GC011-411

Details and patient eligibility

About

It is a single-arm, open-label clinical study to assess the safety and efficacy of the Anti-CD19 Universal CAR-T Cells injection for patients with CD19+ refractory/relapsed B cell acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma.

Full description

The study consists of the following periods: screening, lymphodepletion, CAR-T cell infusion, safety follow up, and long term follow-up.

Enrollment

15 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  1. Eastern Cooperative Oncology Group Performance Status of 0 or 1;
  2. Expected survival time ≥12 weeks;
  3. Adequate hematological, renal and liver function;
  4. Subjects understand and voluntarily sign the informed consent form.

Key Exclusion Criteria:

  1. Positive for any of the following etiological tests: HIV, HBV, HCV, TPPA ;
  2. Cyclophosphamide or fludarabine is contraindicated for subjects ;
  3. Active central nervous system (CNS) involvement by malignancy;
  4. Active infection.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

15 participants in 1 patient group

Anti-CD19 Universal CAR-T Cells injection
Experimental group
Description:
Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion .
Treatment:
Biological: Anti-CD19 Universal CAR-T Cells injection

Trial contacts and locations

1

Loading...

Central trial contact

Sanbin Wang, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems